Search

Soil erosion represents a primary threat to soil systems with adverse implications for ecosystem services, crop production, potable water and carbon storage. While numerous studies have quantified the spatial distribution of aboveground Biomass (AGB), soil erosion and soil organic carbon (SOC) in the Yangtze River Basin (YRB), limited attention has been given to assessing the contributions of different land use types and especially crop types to AGB, soil erosion and SOC. In most studies, cropland is taken as a land use class, while detailed crop types and rotation patterns, and their effect on soil erosion and SOC, vary significantly. In this study, we used the Metronamica model to generate a detailed crop rotation and distribution map across the YRB and subsequently employed the Pan‐European Soil Erosion Risk Assessment (PESERA) model to simulate the spatial distribution of AGB, soil erosion and SOC on a monthly basis. PESERA model simulations indicate an average soil erosion rate across the entire YRB of 7.7 ton/ha/yr, with erosion hotspots concentrated in the Sichuan Basin and the central‐southern regions. The southwestern region and western Sichuan show elevated levels of AGB and SOC, while the eastern plains display lower levels. Erosion rates are lowest in areas designated as artificial land, pasture and grassland, whereas croplands and fruit tree plantations experience the highest erosion rates. In terms of crop types, the highest erosion rates and lowest AGB are observed under fallow and potato cultivation, while the lowest erosion rates and highest AGB are found in rice‐wheat rotation fields. To the best of our knowledge, this is the first study taking detailed crop types and patterns into account while evaluating their effect at a relatively large scale (i.e., YRB). These findings can help to develop sustainable soil management and (cropping) conservation strategies. [ABSTRACT FROM AUTHOR]

Objectives Methods Results Conclusions We aimed to characterize and investigate the safety and efficacy of Plonmarlimab, a novel anti‐granulocyte‐macrophage colony‐stimulating factor (anti‐GM‐CSF) neutralizing antibody, on the treatment of macrophage activation syndrome (MAS), a life‐threatening systemic inflammatory disease, in pre‐clinical models.The binding affinity was evaluated using Biacore. The neutralizing activity was measured through the blockade of ligand–receptor interaction, inhibition of STAT5 phosphorylation and suppression of TF‐1 cell proliferation. The efficacy of Plonmarlimab was evaluated in a humanized MAS model, which was established by engrafting human umbilical cord blood (UCB) cells into NOG‐EXL mice. Additionally, the safety profile of Plonmarlimab was investigated in cynomolgus monkeys.At the molecular level, Plonmarlimab showed sub‐nanomolar binding affinity with human GM‐CSF and effectively blocked the binding of GM‐CSF to its receptor. At the cellular level, Plonmarlimab dose‐dependently inhibited intracellular STAT5 phosphorylation and suppressed GM‐CSF‐induced TF‐1 proliferation. In the UCB‐engrafted NOG‐EXL MAS mouse model, Plonmarlimab treatment significantly ameliorated disease progression, demonstrated by the improvements in body weight loss, anaemia and some histopathological features. Furthermore, Plonmarlimab was well tolerated up to 150 mg/kg weekly in monkeys with no reported adverse effects.Plonmarlimab is a highly potent GM‐CSF blocking antibody and has demonstrated promising efficacy in a pre‐clinical MAS model with a favourable safety profile, supporting its clinical development. [ABSTRACT FROM AUTHOR]